Type III interferon protects swine against foot-and-mouth disease

Journal of Interferon and Cytokine Research

Volumn 34, Issue 10, 2014, Pages 810-821

  Perez Martin, Eva ^a,b   Diaz San Segundo, Fayna ^a   Weiss, Marcelo ^a,b   Sturza, Diego F ^a,b   Dias, Camila C ^a,b   Ramirez Medina, Elizabeth ^a,b   Grubman, Marvin J ^a   De Los Santos, Teresa ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON LAMBDA 3; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FOOT AND MOUTH DISEASE; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; KIDNEY CELL; NONHUMAN; PRIORITY JOURNAL; VIREMIA; VIRUS SHEDDING; ADENOVIRIDAE; ANIMAL; BIOLOGICAL THERAPY; BOVINE; CELL CULTURE; FOOT-AND-MOUTH DISEASE; GENE EXPRESSION PROFILING; GENE VECTOR; GENETICS; IMMUNOLOGY; MONOCYTE; PIG; PROCEDURES; SWINE DISEASES;

ANIMALIA; BOS; BOVINAE; HUMAN ADENOVIRUS TYPE 5; SUIDAE; SUS;

ADENOVIRIDAE; ANIMALS; BIOLOGICAL THERAPY; CATTLE; CELLS, CULTURED; FOOT-AND-MOUTH DISEASE; GENE EXPRESSION PROFILING; GENETIC VECTORS; HUMANS; INTERLEUKINS; MONOCYTES; SWINE; SWINE DISEASES;

EID: 84908262146     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0112     Document Type: Article

References (51)

1. Alexandersen S, Zhan Z, Donaldson AI. 2002. Aspects of the persistence of foot-and-mouth disease virus in animals - the carrier problem. Microbes Infect 4: 1099-1110.
2. Alexandersen S, Zhang Z, Donaldson AI, Garland AJ. 2003. The pathogenesis and diagnosis of foot-and-mouth disease. J Comp Pathol 129: 1-36.
3. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR. 2008. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180: 2474-2485.
4. Ank N, West H, Paludan SR. 2006. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 26: 373-379.
5. Arzt J, Pacheco JM, Rodriguez LL. 2010. The early pathogenesis of foot-and-mouth disease in cattle after aerosol inoculation: identification of the nasopharynx as the primary site of infection. Vet Pathol 47: 1048-1063.
6. Brown CC, Olander HJ, Meyer RF. 1995. Pathogenesis of footand- mouth disease in swine, studied by in situ hybridization. J Comp Pathol 113: 51-58.
7. Callahan JD, Brown F, Osorio FA, Sur JH, Kramer E, Long GW, Lubroth J, Ellis SJ, Shoulars KS, Gaffney KL, Rock DL, Nelson WM. 2002. Use of a portable real-time reverse transcriptase- polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus. J Am Vet Med Assoc 220: 1636-1642.
8. Chase-Topping ME, Handel I, Bankowski BM, Juleff ND, Gibson D, Cox SJ, Windsor MA, Reid E, Doel C, Howey R, Barnett PV, Woolhouse ME, Charleston B. 2013. Understanding foot-and-mouth disease virus transmission biology: identification of the indicators of infectiousness. Vet Res 44: 46-56.
9. Chinsangaram J, Koster M, Grubman MJ. 2001. Inhibition of L-deleted foot-and-mouth disease virus replication by alpha/ beta interferon involves double-stranded RNA-dependent protein kinase. J Virol 12: 5498-5503.
10. Chinsangaram J, Moraes MP, Koster M, Grubman MJ. 2003. Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J Virol 77: 1621-1625.
11. Chinsangaram J, Piccone ME, Grubman MJ. 1999. Ability of foot-and-mouth disease virus to form plaques in cell culture is associated with suppression of alpha/beta interferon. J Virol 73: 9891-9898.
12. de los Santos T, de Avila Botton S, Weiblen R, Grubman MJ. 2006 The leader proteinase of foot-and-mouth disease virus inhibits the induction of beta interferon mRNA and blocks the host innate immune response. J Virol 80: 1906-1914.
13. Dias CC, Moraes MP, Diaz-San Segundo F, de los Santos T, Grubman MJ. 2011. Porcine type I interferon rapidly protects swine against challenge with multiple serotypes of foot-and-mouth disease virus. J Interferon Cytokine Res 31: 227-236.
14. Diaz-San Segundo F, Dias CCA, Moraes MP, Weiss M, Perez- Martin E, Owens G, Custer M, Kamrud K, de los Santos T, Grubman MJ. 2013. Venezuelan equine encephalitis replicon particles can induce rapid protection against foot-and-mouth disease virus. J Virol 87: 5447-5460.
15. Diaz-San Segundo F, Moraes MP, de los Santos T, Dias CC, Grubman MJ. 2010. Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression. J Virol 84: 2063-2077.
16. Diaz-San Segundo F, Weiss M, Perez-Martin E, Koster MJ, Zhu J, Grubman MJ, de los Santos T. 2011. Antiviral activity of bovine type III interferon against foot-and-mouth disease virus. Virology 413: 283-292.
17. Dillon MB. 2011. Skin as a potential source of infectious foot and mouth disease aerosols Proc Biol Sci 278: 1761-1769.
18. Doel TR. 2003. FMD vaccines. Virus Res 91: 81-99.
19. Durand S, Murphy C, Zhang Z, Alexandersen S. 2008. Epithelial distribution and replication of foot-and-mouth disease virus RNA in infected pigs. J Comp Pathol 139: 86-96.
20. Fensterl V, Sen GC. 2009. Interferons and viral infections. Biofactors 35: 14-20.
21. Fray MD, Mann GE, Charleston B. 2001. Validation of an Mx/ CAT reporter gene assay for the quantification of bovine type-I interferon. J Immunol Methods 249: 235-244.
22. Grubman MJ, Baxt B. 2004. Foot-and-mouth disease. Clin Microbiol Rev 17: 465-493.
23. Grubman MJ, Moraes MP, Schutta C, Barrera J, Neilan J, Ettyreddy D, Butman BT, Brough DE, Brake DA. 2010. Adenovirus serotype 5-vectored foot-and-mouth disease subunit vaccines: the first decade. Future Virol 5: 51-64.
24. Grubman MJ, Robertson BH, Morgan DO, Moore DM, Dowbenko D. 1984. Biochemical map of polypeptides specified by foot-and-mouth disease virus. J Virol 50: 579-586.
25. Ioannidis I, Ye F, McNally B, Willette M, Flaño E. 2013. Tolllike receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol 87: 3261-3270.
26. Kotenko S. 2011. IFN-ls. Curr Opin Immunol 23: 583-590.
27. Kotenko S, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69-77.
28. Lind K, Richardson SJ, Leete P, Morgan NG, Korsgren O, Flodström-Tullberg M. 2013. Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets. J Virol 87: 7646-7654.
29. Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, Williams DE. 2009. Interferon lambda as a potential new therapeutic for hepatitis C. Ann N Y Acad Sci 1182: 80-87.
30. Moraes MP, Chinsangaram J, Brum MCS, Grubman MJ. 2003. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 22: 268-279.
31. Moraes MP, de los Santos T, Koster M, Turecek T, Wang H, Andreyev VG, Grubman MJ. 2007. Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J Virol 81: 7124-7135.
32. Moraes MP, Mayr GA, Grubman MJ. 2001. pAd5-Blue: an easy to use, efficient, direct ligation system for engineering recombinant adenovirus constructs. Biotechniques 31: 1050-1056.
33. Moraes MP, Mayr GA, Mason PW, Grubman MJ. 2002. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20: 1631-1639.
34. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, Staeheli P. 2008. Interferon lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 4: e1000151.
35. Pacheco JM, Arzt J, Rodriguez LL. 2010. Early events in the pathogenesis of foot-and-mouth disease in cattle after controlled aerosol exposure. Vet J 183: 46-53.
36. Pacheco JM, Tucker M, Hartwig E, Bishop E, Arzt J, Rodriguez LL. 2012. Direct contact transmission of three different footand- mouth disease virus strains in swine demonstrates important strain-specific differences. Vet J 193: 456-463.
37. Perez-Martin E, Weiss M, Diaz-San Segundo F, Pacheco JM, Arzt J, Grubman MJ, de los Santos T. 2012. Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle. J Virol 86: 4477-4487.
38. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, Staeheli P, Hornef MW. 2011. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 108: 7944-7949.
39. Pulverer JE, Rand U, Lienenklaus S, Kugel D, Zietara N, Kochs G, Naumann R, Weiss S, Staeheli P, Hauser H, Köster M. 2010. Temporal and spatial resolution of type I and III interferon responses in vivo. J Virol 84: 8626-8638.
40. Rieder E, Bunch T, Brown F, Mason PW. 1993. Genetically engineered foot-and-mouth disease viruses with poly (C) tracts of two nucleotides are virulent in mice. J Virol 67: 5139-5145.
41. Rodriguez LL, Grubman MJ. 2009. Foot and mouth disease virus vaccines. Vaccine 27 Suppl 4: D90-D94.
42. Salt JS. 1993. The carrier state in foot and mouth disease-an immunological review. Br Vet J 149: 207-223.
43. Samuel CE. 2001. Antiviral actions of interferons. Clin Microbiol Rev 14: 778-809.
44. Sang Y, Rowland RRR, Blecha F. 2010. Molecular characterization and antiviral analyses of porcine type III interferons. J Interferon Cytokine Res 30: 1-7.
45. Schoggins JW, Rice CM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 1: 519-525.
46. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL- 28R. Nat Immunol 4: 63-68.
47. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFNlambda is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4: e1000017.
48. Sorensen KJ, Madsen KG, Madsen ES, Salt JS, Nquindi J, Mackay DKJ. 1998. Differentiation of infection from vaccination in foot-and-mouth disease by the detection of antibodies to the non-structural proteins 3D, 3AB and 3ABC in ELISA using antigens expressed in baculovirus. Arch Virol 143: 1461-1476.
49. Uze G, Schreiber G, Piehler J, Pellegrini S. 2007. The receptor of the type I interferon family. Curr Top Microbiol Immunol 316: 71-95.
50. Wang D, Fang L, Liu L, Zhong H, Chen Q, Luo R, Liu X, Zhang Z, Chen H, Xiao S. 2011b. Foot-and-mouth disease virus (FMDV) leader proteinase negatively regulates the porcine interferon-l1 pathway. Mol Immunol 49: 407-412.
51. Wang D, Fang L, Zhao F, Luo R, Chen H, Xiao S. 2011a. Molecular cloning, expression and antiviral activity of porcine interleukin-29 (poIL-29). Dev Comp Immunol 35: 378-384.